CA2961813A1 - Uses of neuregulin in preventing, treating or delaying ventricular arrhythmia, and composition thereof - Google Patents
Uses of neuregulin in preventing, treating or delaying ventricular arrhythmia, and composition thereof Download PDFInfo
- Publication number
- CA2961813A1 CA2961813A1 CA2961813A CA2961813A CA2961813A1 CA 2961813 A1 CA2961813 A1 CA 2961813A1 CA 2961813 A CA2961813 A CA 2961813A CA 2961813 A CA2961813 A CA 2961813A CA 2961813 A1 CA2961813 A1 CA 2961813A1
- Authority
- CA
- Canada
- Prior art keywords
- ventricular
- nrg
- treating
- neuregulin
- vpb
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 206010047281 Ventricular arrhythmia Diseases 0.000 title claims abstract description 63
- 239000000203 mixture Substances 0.000 title claims description 9
- 108050003475 Neuregulin Proteins 0.000 title abstract description 40
- 102000014413 Neuregulin Human genes 0.000 title abstract description 39
- 239000003814 drug Substances 0.000 claims abstract description 26
- 229940079593 drug Drugs 0.000 claims abstract description 22
- 239000000825 pharmaceutical preparation Substances 0.000 claims abstract description 17
- 238000002360 preparation method Methods 0.000 claims abstract description 3
- 230000002861 ventricular Effects 0.000 claims description 33
- 206010047302 ventricular tachycardia Diseases 0.000 claims description 31
- 208000000418 Premature Cardiac Complexes Diseases 0.000 claims description 30
- 208000003663 ventricular fibrillation Diseases 0.000 claims description 28
- 241000124008 Mammalia Species 0.000 claims description 12
- 102100040896 Growth/differentiation factor 15 Human genes 0.000 claims description 8
- 101000893549 Homo sapiens Growth/differentiation factor 15 Proteins 0.000 claims description 8
- 101000653754 Rattus norvegicus Sphingosine 1-phosphate receptor 5 Proteins 0.000 claims description 8
- 239000003195 sodium channel blocking agent Substances 0.000 claims description 5
- ZOXZWYWOECCBSH-UHFFFAOYSA-N 4 Methyl N-ethylcathinone Chemical compound CCNC(C)C(=O)C1=CC=C(C)C=C1 ZOXZWYWOECCBSH-UHFFFAOYSA-N 0.000 claims description 4
- 102400000057 Neuregulin-2 Human genes 0.000 claims description 4
- 101800000675 Neuregulin-2 Proteins 0.000 claims description 4
- 102400000054 Neuregulin-3 Human genes 0.000 claims description 4
- 101800000673 Neuregulin-3 Proteins 0.000 claims description 4
- 101800002641 Neuregulin-4 Proteins 0.000 claims description 4
- 102400000055 Neuregulin-4 Human genes 0.000 claims description 3
- 229940125794 sodium channel blocker Drugs 0.000 claims description 3
- 108060003345 Adrenergic Receptor Proteins 0.000 claims description 2
- 102000017910 Adrenergic receptor Human genes 0.000 claims description 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 239000003087 receptor blocking agent Substances 0.000 claims 1
- 230000008859 change Effects 0.000 description 23
- 239000000902 placebo Substances 0.000 description 23
- 229940068196 placebo Drugs 0.000 description 23
- 238000002565 electrocardiography Methods 0.000 description 22
- 210000004027 cell Anatomy 0.000 description 19
- 206010003119 arrhythmia Diseases 0.000 description 15
- 108050002150 EGF-like domains Proteins 0.000 description 14
- 102000012545 EGF-like domains Human genes 0.000 description 14
- 230000006793 arrhythmia Effects 0.000 description 14
- 230000002159 abnormal effect Effects 0.000 description 13
- 210000002216 heart Anatomy 0.000 description 12
- 206010019280 Heart failures Diseases 0.000 description 11
- 238000000034 method Methods 0.000 description 11
- 238000003745 diagnosis Methods 0.000 description 10
- 230000000694 effects Effects 0.000 description 10
- 102000005962 receptors Human genes 0.000 description 10
- 108020003175 receptors Proteins 0.000 description 10
- 150000001413 amino acids Chemical group 0.000 description 9
- 230000002107 myocardial effect Effects 0.000 description 9
- 102000048238 Neuregulin-1 Human genes 0.000 description 8
- 108090000556 Neuregulin-1 Proteins 0.000 description 8
- 239000012634 fragment Substances 0.000 description 7
- 108090000623 proteins and genes Proteins 0.000 description 7
- 102000001301 EGF receptor Human genes 0.000 description 6
- 108060006698 EGF receptor Proteins 0.000 description 6
- 239000003416 antiarrhythmic agent Substances 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- 230000006870 function Effects 0.000 description 6
- 108090000765 processed proteins & peptides Proteins 0.000 description 6
- 208000024172 Cardiovascular disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 230000001965 increasing effect Effects 0.000 description 5
- 102000004196 processed proteins & peptides Human genes 0.000 description 5
- 230000004083 survival effect Effects 0.000 description 5
- 238000011282 treatment Methods 0.000 description 5
- 206010007558 Cardiac failure chronic Diseases 0.000 description 4
- 108010052164 Sodium Channels Proteins 0.000 description 4
- 102000018674 Sodium Channels Human genes 0.000 description 4
- 230000004069 differentiation Effects 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000019622 heart disease Diseases 0.000 description 4
- 230000003834 intracellular effect Effects 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- AQHHHDLHHXJYJD-UHFFFAOYSA-N propranolol Chemical compound C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 description 4
- 230000002336 repolarization Effects 0.000 description 4
- 210000001013 sinoatrial node Anatomy 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 206010003658 Atrial Fibrillation Diseases 0.000 description 3
- 206010007559 Cardiac failure congestive Diseases 0.000 description 3
- 102100031968 Ephrin type-B receptor 2 Human genes 0.000 description 3
- 102000001708 Protein Isoforms Human genes 0.000 description 3
- 108010029485 Protein Isoforms Proteins 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- IYIKLHRQXLHMJQ-UHFFFAOYSA-N amiodarone Chemical compound CCCCC=1OC2=CC=CC=C2C=1C(=O)C1=CC(I)=C(OCCN(CC)CC)C(I)=C1 IYIKLHRQXLHMJQ-UHFFFAOYSA-N 0.000 description 3
- 229960005260 amiodarone Drugs 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 230000000747 cardiac effect Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 230000004217 heart function Effects 0.000 description 3
- 238000001802 infusion Methods 0.000 description 3
- 210000004897 n-terminal region Anatomy 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 230000033764 rhythmic process Effects 0.000 description 3
- 238000004904 shortening Methods 0.000 description 3
- 230000019491 signal transduction Effects 0.000 description 3
- 206010003130 Arrhythmia supraventricular Diseases 0.000 description 2
- 206010003671 Atrioventricular Block Diseases 0.000 description 2
- 229940127291 Calcium channel antagonist Drugs 0.000 description 2
- 108091006146 Channels Proteins 0.000 description 2
- 208000014526 Conduction disease Diseases 0.000 description 2
- 206010015856 Extrasystoles Diseases 0.000 description 2
- DJBNUMBKLMJRSA-UHFFFAOYSA-N Flecainide Chemical compound FC(F)(F)COC1=CC=C(OCC(F)(F)F)C(C(=O)NCC2NCCCC2)=C1 DJBNUMBKLMJRSA-UHFFFAOYSA-N 0.000 description 2
- 101001109800 Homo sapiens Pro-neuregulin-1, membrane-bound isoform Proteins 0.000 description 2
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 208000029578 Muscle disease Diseases 0.000 description 2
- 102000004278 Receptor Protein-Tyrosine Kinases Human genes 0.000 description 2
- 108090000873 Receptor Protein-Tyrosine Kinases Proteins 0.000 description 2
- 208000004301 Sinus Arrhythmia Diseases 0.000 description 2
- 206010042434 Sudden death Diseases 0.000 description 2
- 208000009729 Ventricular Premature Complexes Diseases 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 206010000891 acute myocardial infarction Diseases 0.000 description 2
- 230000008827 biological function Effects 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 210000004899 c-terminal region Anatomy 0.000 description 2
- 210000004413 cardiac myocyte Anatomy 0.000 description 2
- 238000007675 cardiac surgery Methods 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 210000004292 cytoskeleton Anatomy 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 239000003792 electrolyte Substances 0.000 description 2
- 230000007717 exclusion Effects 0.000 description 2
- 229960000449 flecainide Drugs 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 230000001121 heart beat frequency Effects 0.000 description 2
- 102000055650 human NRG1 Human genes 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 229960004194 lidocaine Drugs 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 238000004393 prognosis Methods 0.000 description 2
- 229960003712 propranolol Drugs 0.000 description 2
- LOUPRKONTZGTKE-LHHVKLHASA-N quinidine Chemical compound C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@H]2[C@@H](O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-LHHVKLHASA-N 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 208000004124 rheumatic heart disease Diseases 0.000 description 2
- 210000002235 sarcomere Anatomy 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 230000008054 signal transmission Effects 0.000 description 2
- 238000011272 standard treatment Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 102000035160 transmembrane proteins Human genes 0.000 description 2
- 108091005703 transmembrane proteins Proteins 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- SGTNSNPWRIOYBX-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC=C(OC)C(OC)=C1 SGTNSNPWRIOYBX-UHFFFAOYSA-N 0.000 description 1
- 208000001193 Accelerated Idioventricular Rhythm Diseases 0.000 description 1
- HMRWQTHUDVXMGH-GUBZILKMSA-N Ala-Glu-Lys Chemical compound C[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@H](C(O)=O)CCCCN HMRWQTHUDVXMGH-GUBZILKMSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 108090000312 Calcium Channels Proteins 0.000 description 1
- 102000003922 Calcium Channels Human genes 0.000 description 1
- 206010007513 Cardiac aneurysm Diseases 0.000 description 1
- 206010007572 Cardiac hypertrophy Diseases 0.000 description 1
- 208000031229 Cardiomyopathies Diseases 0.000 description 1
- 108010009685 Cholinergic Receptors Proteins 0.000 description 1
- 206010009244 Claustrophobia Diseases 0.000 description 1
- 208000002330 Congenital Heart Defects Diseases 0.000 description 1
- BSGXXYRIDXUEOM-IHRRRGAJSA-N Cys-Phe-Met Chemical compound CSCC[C@@H](C(=O)O)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CS)N BSGXXYRIDXUEOM-IHRRRGAJSA-N 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 208000017701 Endocrine disease Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000056372 ErbB-3 Receptor Human genes 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- QDMVXRNLOPTPIE-WDCWCFNPSA-N Glu-Lys-Thr Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O QDMVXRNLOPTPIE-WDCWCFNPSA-N 0.000 description 1
- GDOZQTNZPCUARW-YFKPBYRVSA-N Gly-Gly-Glu Chemical compound NCC(=O)NCC(=O)N[C@H](C(O)=O)CCC(O)=O GDOZQTNZPCUARW-YFKPBYRVSA-N 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 208000010271 Heart Block Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101001109792 Homo sapiens Pro-neuregulin-2, membrane-bound isoform Proteins 0.000 description 1
- 101001109765 Homo sapiens Pro-neuregulin-3, membrane-bound isoform Proteins 0.000 description 1
- 101001109767 Homo sapiens Pro-neuregulin-4, membrane-bound isoform Proteins 0.000 description 1
- 206010021113 Hypothermia Diseases 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- KZZCOWMDDXDKSS-CIUDSAMLSA-N Leu-Ser-Asn Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(O)=O KZZCOWMDDXDKSS-CIUDSAMLSA-N 0.000 description 1
- 238000000585 Mann–Whitney U test Methods 0.000 description 1
- 102000005741 Metalloproteases Human genes 0.000 description 1
- 108010006035 Metalloproteases Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 208000021642 Muscular disease Diseases 0.000 description 1
- 208000009525 Myocarditis Diseases 0.000 description 1
- 102400001263 NT-proBNP Human genes 0.000 description 1
- 102400000058 Neuregulin-1 Human genes 0.000 description 1
- 206010034487 Pericarditis constrictive Diseases 0.000 description 1
- OWCLJDXHHZUNEL-IHRRRGAJSA-N Phe-Cys-Val Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(O)=O OWCLJDXHHZUNEL-IHRRRGAJSA-N 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 208000008376 Pre-Excitation Syndromes Diseases 0.000 description 1
- 102100022668 Pro-neuregulin-2, membrane-bound isoform Human genes 0.000 description 1
- 102100022659 Pro-neuregulin-3, membrane-bound isoform Human genes 0.000 description 1
- 102100022658 Pro-neuregulin-4, membrane-bound isoform Human genes 0.000 description 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 1
- 101710100969 Receptor tyrosine-protein kinase erbB-3 Proteins 0.000 description 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
- 208000001871 Tachycardia Diseases 0.000 description 1
- 208000018452 Torsade de pointes Diseases 0.000 description 1
- 208000002363 Torsades de Pointes Diseases 0.000 description 1
- 206010070863 Toxicity to various agents Diseases 0.000 description 1
- 229940123445 Tricyclic antidepressant Drugs 0.000 description 1
- -1 Urine Test Substances 0.000 description 1
- KTEZUXISLQTDDQ-NHCYSSNCSA-N Val-Lys-Asp Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(=O)O)C(=O)O)N KTEZUXISLQTDDQ-NHCYSSNCSA-N 0.000 description 1
- 208000008131 Ventricular Flutter Diseases 0.000 description 1
- 206010058184 Ventricular parasystole Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 102000034337 acetylcholine receptors Human genes 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000001919 adrenal effect Effects 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 108010077245 asparaginyl-proline Proteins 0.000 description 1
- 230000002567 autonomic effect Effects 0.000 description 1
- 102000012740 beta Adrenergic Receptors Human genes 0.000 description 1
- 108010079452 beta Adrenergic Receptors Proteins 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000012292 cell migration Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000017455 cell-cell adhesion Effects 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 230000007213 cerebrovascular event Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- LOUPRKONTZGTKE-UHFFFAOYSA-N cinchonine Natural products C1C(C(C2)C=C)CCN2C1C(O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-UHFFFAOYSA-N 0.000 description 1
- 238000010224 classification analysis Methods 0.000 description 1
- 238000009535 clinical urine test Methods 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 208000028831 congenital heart disease Diseases 0.000 description 1
- 208000000839 constrictive pericarditis Diseases 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 229940000406 drug candidate Drugs 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000013020 embryo development Effects 0.000 description 1
- 210000001174 endocardium Anatomy 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 238000003209 gene knockout Methods 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 230000010005 growth-factor like effect Effects 0.000 description 1
- 231100001261 hazardous Toxicity 0.000 description 1
- 230000009067 heart development Effects 0.000 description 1
- 239000000833 heterodimer Substances 0.000 description 1
- 239000000710 homodimer Substances 0.000 description 1
- 206010020871 hypertrophic cardiomyopathy Diseases 0.000 description 1
- 230000002631 hypothermal effect Effects 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 210000004692 intercellular junction Anatomy 0.000 description 1
- 230000035987 intoxication Effects 0.000 description 1
- 231100000566 intoxication Toxicity 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 108020001756 ligand binding domains Proteins 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 108010009298 lysylglutamic acid Proteins 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 210000005075 mammary gland Anatomy 0.000 description 1
- 231100000682 maximum tolerated dose Toxicity 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000028161 membrane depolarization Effects 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 210000000663 muscle cell Anatomy 0.000 description 1
- 230000004220 muscle function Effects 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 210000004789 organ system Anatomy 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 230000003076 paracrine Effects 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 208000019899 phobic disease Diseases 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000009597 pregnancy test Methods 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 108010008064 pro-brain natriuretic peptide (1-76) Proteins 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 208000002815 pulmonary hypertension Diseases 0.000 description 1
- 238000000306 qrs interval Methods 0.000 description 1
- 238000013441 quality evaluation Methods 0.000 description 1
- 229960001404 quinidine Drugs 0.000 description 1
- 238000002601 radiography Methods 0.000 description 1
- 230000036647 reaction Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000013577 regulation of ventricular cardiomyocyte membrane repolarization Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 201000000980 schizophrenia Diseases 0.000 description 1
- 102000034285 signal transducing proteins Human genes 0.000 description 1
- 108091006024 signal transducing proteins Proteins 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 210000002363 skeletal muscle cell Anatomy 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 238000011301 standard therapy Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 230000035488 systolic blood pressure Effects 0.000 description 1
- 230000006794 tachycardia Effects 0.000 description 1
- 210000000115 thoracic cavity Anatomy 0.000 description 1
- 239000003029 tricyclic antidepressant agent Substances 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 229960001722 verapamil Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1883—Neuregulins, e.g.. p185erbB2 ligands, glial growth factor, heregulin, ARIA, neu differentiation factor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Heart & Thoracic Surgery (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cardiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410529437.4 | 2014-09-24 | ||
| CN201410529437.4A CN105497876B (zh) | 2014-09-24 | 2014-09-24 | 神经调节蛋白用于预防、治疗或延迟心脏室性心律失常的方法和组合物 |
| PCT/CN2015/088972 WO2016045493A1 (zh) | 2014-09-24 | 2015-09-06 | 神经调节蛋白预防、治疗或延迟室性心律失常的用途及其组合物 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2961813A1 true CA2961813A1 (en) | 2016-03-31 |
Family
ID=55580273
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2961813A Abandoned CA2961813A1 (en) | 2014-09-24 | 2015-09-06 | Uses of neuregulin in preventing, treating or delaying ventricular arrhythmia, and composition thereof |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US10441633B2 (enExample) |
| EP (1) | EP3199174B1 (enExample) |
| JP (1) | JP2017530127A (enExample) |
| KR (1) | KR20170055492A (enExample) |
| CN (2) | CN105497876B (enExample) |
| AU (1) | AU2015320230B2 (enExample) |
| CA (1) | CA2961813A1 (enExample) |
| RU (1) | RU2017113775A (enExample) |
| WO (1) | WO2016045493A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0620819A2 (pt) | 2005-12-30 | 2011-11-22 | Zensun Shangai Science & Technology Ltd | uso de uma neuregulina (nrg) de liberação prolongada, nrg em uma liberação prolongada de uma dosagem baixa constante, e, composição de liberação prolongada para prevenir, tratar ou retardar uma doença ou distúrbio em um mamìfero |
| JP6096262B2 (ja) | 2009-08-25 | 2017-03-15 | ゼンサン （シャンハイ） サイエンス アンド テクノロジー，シーオー．，エルティーディー． | ニューレグリンに基づく心不全の治療方法 |
| WO2013053076A1 (en) | 2011-10-10 | 2013-04-18 | Zensun （Shanghai）Science & Technology Limited | Compositions and methods for treating heart failure |
| JP6475623B2 (ja) | 2012-10-08 | 2019-02-27 | ゼンスン（シャンハイ）サイエンス アンド テクノロジー カンパニー リミテッド | 糖尿病患者における心不全の治療用組成物 |
| CA2911848A1 (en) | 2013-05-22 | 2014-11-27 | Zensun (Shanghai) Science & Technology, Ltd. | Extended release of neuregulin for treating heart failure |
| CN110946993A (zh) | 2014-01-03 | 2020-04-03 | 上海泽生科技开发股份有限公司 | 纽兰格林制剂的配方 |
| CN105561298A (zh) | 2014-10-17 | 2016-05-11 | 上海泽生科技开发有限公司 | 神经调节蛋白用于预防、治疗或延迟射血分数保留的心力衰竭的方法和组合物 |
| WO2020037076A1 (en) * | 2018-08-14 | 2020-02-20 | Emory University | Inducing proliferation of cardiomyocytes and therapeutic uses related thereto |
| AR121035A1 (es) | 2019-04-01 | 2022-04-13 | Lilly Co Eli | Compuestos de neuregulina-4 y métodos de uso |
| JP2022547335A (ja) * | 2019-09-16 | 2022-11-11 | ゼンサン （シャンハイ） サイエンス アンド テクノロジー，シーオー．，エルティーディー． | 組換えヒトニューレグリン誘導体及びその使用 |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7115554B1 (en) | 1993-05-06 | 2006-10-03 | Acorda Therapeutics, Inc. | Methods of increasing myotube formation or survival or muscle cell mitogenesis differentiation or survival using neuregulin GGF III |
| US5716930A (en) | 1991-04-10 | 1998-02-10 | Ludwig Institute For Cancer Research | Glial growth factors |
| US5530109A (en) | 1991-04-10 | 1996-06-25 | Ludwig Institute For Cancer Research | DNA encoding glial mitogenic factors |
| US5834229A (en) | 1991-05-24 | 1998-11-10 | Genentech, Inc. | Nucleic acids vectors and host cells encoding and expressing heregulin 2-α |
| US5912326A (en) | 1995-09-08 | 1999-06-15 | President And Fellows Of Harvard College | Cerebellum-derived growth factors |
| CA2306228A1 (en) | 1997-10-14 | 1999-04-22 | Cambridge Neuroscience, Inc. | Therapeutic methods comprising use of a neuregulin |
| AUPP785098A0 (en) | 1998-12-21 | 1999-01-21 | Victor Chang Cardiac Research Institute, The | Treatment of heart disease |
| US6635249B1 (en) | 1999-04-23 | 2003-10-21 | Cenes Pharmaceuticals, Inc. | Methods for treating congestive heart failure |
| CN1138785C (zh) | 1999-06-04 | 2004-02-18 | 周明东 | 生长因子神经调节蛋白及其类似物的新应用 |
| AUPQ105799A0 (en) | 1999-06-18 | 1999-07-08 | Victor Chang Cardiac Research Institute, The | Cell growth inhibition |
| WO2003099320A1 (en) | 2002-05-24 | 2003-12-04 | Zensun (Shanghai) Sci-Tech.Ltd | Neuregulin based methods and compositions for treating viral myocarditis and dilated cardiomyopathy |
| CN1498656A (zh) * | 2002-11-08 | 2004-05-26 | 上海泽生科技开发有限公司 | 神经调节蛋白用于心肌梗死治疗的方法和组合物 |
| AU2006206778A1 (en) | 2005-01-20 | 2006-07-27 | Schuchean Chien | Methods for QT interval control |
| US20070213264A1 (en) | 2005-12-02 | 2007-09-13 | Mingdong Zhou | Neuregulin variants and methods of screening and using thereof |
| BRPI0620819A2 (pt) | 2005-12-30 | 2011-11-22 | Zensun Shangai Science & Technology Ltd | uso de uma neuregulina (nrg) de liberação prolongada, nrg em uma liberação prolongada de uma dosagem baixa constante, e, composição de liberação prolongada para prevenir, tratar ou retardar uma doença ou distúrbio em um mamìfero |
| US9580515B2 (en) | 2006-08-21 | 2017-02-28 | Zensun (Shanghai) Science & Technology, Co., Ltd. | Neukinase, a downstream protein of neuregulin |
| CN101310766B (zh) * | 2007-05-25 | 2014-04-16 | 上海泽生科技开发有限公司 | 神经调节蛋白的新用途 |
| US20090156488A1 (en) | 2007-09-12 | 2009-06-18 | Zensun (Shanghai) Science & Technology Limited | Use of neuregulin for organ preservation |
| US8603817B2 (en) * | 2008-11-03 | 2013-12-10 | University Of Washington | Induction of human embryonic stem cell derived cardiac pacemaker or chamber-type cardiomyocytes by manipulation of neuregulin signaling |
| EP2808339B1 (en) | 2008-11-28 | 2017-02-15 | Zensun (Shanghai) Science & Technology, Co., Ltd. | Neuregulin peptides and their use |
| WO2010060266A1 (en) | 2008-11-28 | 2010-06-03 | Zensun (Shanghai) Science & Technology Limited | Neuregulin and cardiac stem cells |
| CN102470161A (zh) | 2009-06-09 | 2012-05-23 | 上海泽生科技开发有限公司 | 神经调节蛋白用于治疗心力衰竭的有效剂量 |
| WO2010142141A1 (en) | 2009-06-09 | 2010-12-16 | Zensun (Shanghai) Science & Technology Limited | Neuregulin based methods for treating heart failure |
| CN102139095A (zh) | 2010-01-29 | 2011-08-03 | 上海泽生科技开发有限公司 | 神经调节蛋白用于预防、治疗或延迟心脏缺血再灌注损伤的方法和组合物 |
| EP2555788B1 (en) * | 2010-03-24 | 2017-10-11 | Massachusetts Institute of Technology | NEUREGULIN DIMER FOR AN ErbB/HER RECEPTOR FOR USE IN REDUCING CARDIOTOXICITY. |
| US20120028992A1 (en) * | 2010-08-02 | 2012-02-02 | Brown Arthur M | Pharmaceutical compositions for terminating acute episodes of cardiac arrhythmia, restoring sinus rhythm, preventing recurrence of cardiac arrhythmia and/or maintaining normal sinus rhythm in mammals |
| WO2012054718A2 (en) | 2010-10-22 | 2012-04-26 | The General Hospital Corporation | Treating long qt syndrome |
| CN102302552A (zh) * | 2011-08-31 | 2012-01-04 | 朱明军 | 一种治疗心律失常的胶囊及其制备方法 |
| WO2013053076A1 (en) | 2011-10-10 | 2013-04-18 | Zensun （Shanghai）Science & Technology Limited | Compositions and methods for treating heart failure |
| JP6475623B2 (ja) | 2012-10-08 | 2019-02-27 | ゼンスン（シャンハイ）サイエンス アンド テクノロジー カンパニー リミテッド | 糖尿病患者における心不全の治療用組成物 |
| CA2911848A1 (en) | 2013-05-22 | 2014-11-27 | Zensun (Shanghai) Science & Technology, Ltd. | Extended release of neuregulin for treating heart failure |
| SG11201600119PA (en) | 2013-08-01 | 2016-02-26 | Gilead Sciences Inc | Compound and methods for treating long qt syndrome |
| CN104758300A (zh) | 2014-01-02 | 2015-07-08 | 上海泽生科技开发有限公司 | 维生素d及其组合物的抗菌用途 |
| CN110946993A (zh) | 2014-01-03 | 2020-04-03 | 上海泽生科技开发股份有限公司 | 纽兰格林制剂的配方 |
| CN105561298A (zh) | 2014-10-17 | 2016-05-11 | 上海泽生科技开发有限公司 | 神经调节蛋白用于预防、治疗或延迟射血分数保留的心力衰竭的方法和组合物 |
-
2014
- 2014-09-24 CN CN201410529437.4A patent/CN105497876B/zh active Active
-
2015
- 2015-09-06 JP JP2017516166A patent/JP2017530127A/ja active Pending
- 2015-09-06 US US15/513,939 patent/US10441633B2/en active Active
- 2015-09-06 WO PCT/CN2015/088972 patent/WO2016045493A1/zh not_active Ceased
- 2015-09-06 AU AU2015320230A patent/AU2015320230B2/en active Active
- 2015-09-06 KR KR1020177008203A patent/KR20170055492A/ko not_active Withdrawn
- 2015-09-06 CN CN201580050316.4A patent/CN110337304A/zh active Pending
- 2015-09-06 EP EP15845381.1A patent/EP3199174B1/en not_active Revoked
- 2015-09-06 CA CA2961813A patent/CA2961813A1/en not_active Abandoned
- 2015-09-06 RU RU2017113775A patent/RU2017113775A/ru not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| AU2015320230A1 (en) | 2017-03-30 |
| CN105497876A (zh) | 2016-04-20 |
| EP3199174A1 (en) | 2017-08-02 |
| WO2016045493A1 (zh) | 2016-03-31 |
| US10441633B2 (en) | 2019-10-15 |
| EP3199174B1 (en) | 2022-04-13 |
| RU2017113775A (ru) | 2018-10-26 |
| JP2017530127A (ja) | 2017-10-12 |
| EP3199174A4 (en) | 2018-06-06 |
| CN110337304A (zh) | 2019-10-15 |
| AU2015320230B2 (en) | 2021-06-24 |
| US20170368140A1 (en) | 2017-12-28 |
| RU2017113775A3 (enExample) | 2019-04-04 |
| KR20170055492A (ko) | 2017-05-19 |
| CN105497876B (zh) | 2021-01-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10441633B2 (en) | Uses of neuregulin in preventing, treating or delaying ventricular arrhythmia, and composition thereof | |
| JP7761964B2 (ja) | 心不全の治療用組成物 | |
| AU2021258063B2 (en) | Methods and compositions of neuregulins for preventing, treating or delaying preserved ejection fraction cardiac failure | |
| US20130079281A1 (en) | Neuregulin based methods for treating heart failure | |
| US11246909B2 (en) | Neuregulin based methods for treating heart failure | |
| AU2021225283A1 (en) | Method for preventing, treating or delaying heart failure by using neuregulin, and composition | |
| JP2026004564A (ja) | 心不全の治療用組成物および診断キット | |
| CN117797243A (zh) | 神经调节蛋白及其应用 | |
| HK1241737B (en) | Compositions of a neuregulin for preventing, treating or delaying preserved ejection fraction cardiac failure | |
| HK1241737A1 (en) | Compositions of a neuregulin for preventing, treating or delaying preserved ejection fraction cardiac failure |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Discontinued |
Effective date: 20211130 |
|
| FZDE | Discontinued |
Effective date: 20211130 |
|
| FZDE | Discontinued |
Effective date: 20211130 |